Abstract: An aromatic heterocyclic derivative represented by the following formula (1)-1 or (1)-2: wherein in the formula (1)-1 or (1)-2, A is a substituted or unsubstituted nitrogen-containing heterocyclic group including 2 to 30 ring carbon atoms; B is a substituted or unsubstituted aromatic hydrocarbon group including 6 to 30 ring carbon atoms or a substituted or unsubstituted aromatic heterocyclic group including 2 to 30 ring carbon atoms; n is an integer of 2 or more; and Czs are independently an aromatic heterocyclic group including a predetermined structure.

Abstract: The instant invention relates to novel hydroxyphenyl triazine UV-absorbers with an aromatic carbocyclic fused ring system having a long wavelength shifted absorption spectrum with significant absorbance up to 420 nm. Further aspects of the invention are a process for their preparation, a UV stabilized composition containing the new UV-absorbers, a process for the stabilization of organic materials and the use of the new compounds as UV-light stabilizers for organic materials.

Abstract: Provided are novel 2PA-active monomers of the formula: wherein Y?H, acrylic or methacrylic moiety; R is a linear or branched alkyl group, —CmH2m+1, where m=1-6 or an alkylether group, —(CH2CH2O)pMe, where p=1-5. The number of R?—(OH)x groups, attached to the phenyl rings of the triarylamine moiety either in a para or a meta position, could be 3 or 6 per molecule, or mixtures of molecules containing 3, 4, 5, 6 in various ratios and wherein x=1, 2, or 3. R? is a linear or branched alkyl group such as —CmH2m, where m=1-6, i.e. linear —(CH2)m, where m=2-6, or branched alkyl group such as —CH2CH(R?)—, where R??—(CH2)lCH3, where l=2-6.

Abstract: The present invention deals with a laminate useful for forming fully encapsulated flexible printed wiring boards. The laminate comprises a dielectric substrate coated with a curable composition comprising an epoxy and a novel aromatic di-isoimide chemical compound. The curable composition provides the benefit of thermal latency, improving shelf-life, and reducing premature curing during processing. Fully encapsulated printed wiring boards are also disclosed.

Abstract: A phenyl-substituted 1,3,5-triazine compound represented by the general formula (1): wherein Ar1 and Ar2 independently represent substituted or unsubstituted phenyl, naphthyl or biphenylyl group; R1, R2 and R3 independently represent hydrogen atom or methyl group; X1 and X2 independently represent substituted or unsubstituted phenylene, naphthylene or pyridylene group; p and q independently represent an integer of 0 to 2; and Ar3 and Ar4 independently represent substituted or unsubstituted pyridyl or phenyl group. This compound is suitable for an organic electroluminescent device.

Abstract: A compound for an organic photoelectric device, an organic photoelectric device including the same, and a display device including the same the compound being represented by the following Chemical Formula 1:

Abstract: A compound represented by Formula 1 below may be used in an organic light emitting diode.

Abstract: Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Abstract: There is provided a compound having at least one unit of Formula I where Ar1, Ar2, and Ar3 are the same or different and have Formula II In Formula II: R1 is the same or different at each occurrence and is D, alkyl, or silyl, or adjacent R1 groups can be joined together to form a 6-membered fused aromatic ring; Q is the same or different at each occurrence and is phenyl, naphthyl, substituted naphthyl, an N,O,S-heterocycle, or a deuterated analog thereof; a is an integer from 1-5; b is an integer from 0-5, with the proviso that when b=5, c=0; and c is an integer from 0-4. In the compound not all Ar1, Ar2, and Ar3 are the same.

Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.

Abstract: A compound for an organic optoelectronic device, an organic light emitting diode including the same, and a display device including the organic light emitting diode are disclosed, the compound being represented by the following Chemical Formula 1:

Abstract: The invention provides a film comprising at least two layers, Layer A and Layer B, and wherein Layer(A) is formed from a Composition A comprising at least one compound selected from Formula A: wherein Np is selected from 1-naphthyl or 2-naphthyl, and wherein each R is described herein; and wherein Layer B is formed from a Composition B comprising at least one “HTL compound;” and wherein Layer A is not adjacent to Layer B. The invention also provides a composition comprising at least one compound selected from Formula A: wherein each R is described herein, and wherein the compound has a Tg greater than, or equal to, 115° C.

Abstract: A compound of the invention is represented by a formula (1) below. In the formula (1), at least one of A1 and A2 represents a substituted or unsubstituted nitrogen-containing aromatic heterocyclic group. A material for an organic electroluminescence device contains the compound represented by the formula (1). The material for an organic electroluminescence device includes an organic thin-film layer between an anode and a cathode, in which the organic thin-film layer contains the compound represented by the formula (1).

Abstract: The present invention relates to ?-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure ?-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

Abstract: A salt catalyst comprises an ionic complex of i) a nitrogen base comprising one or more guanidine and/or amidine functional groups, and ii) an oxoacid comprising one or more active acid groups, the active acid groups independently comprising a carbonyl group (C?O), sulfoxide group (S?O), and/or a phosphonyl group (P?O) bonded to one or more active hydroxy groups; wherein a ratio of moles of the active hydroxy groups to moles of the guanidine and/or amidine functional groups is greater than 0 and less than 2.0. The salt catalysts are capable of catalyzing ring opening polymerization of cyclic carbonyl compounds.

Abstract: The present invention relates to polymeric materials which have electron-transporting, hole-transporting and/or emitting units in the side chains. The present invention furthermore relates to processes for the preparation of these polymers, to the use of these polymers in electroluminescent devices and to electroluminescent devices comprising these polymers.

Abstract: The present invention provides a new compound and an organic electronic device using the same. The organic electronic device according to the present invention exhibits excellent properties in views of efficiency, driving voltage and a life span.

Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.

Abstract: According to the invention, there is provided a compound represented by a formula (1) below: wherein X represents a residue derived from an aryl ring or a heteroaryl ring, or a single bond, Ar1 and Ar2 respectively represent a phenyl group or heteroaryl group, Ar3 represents a group having 60 or less carbon atoms, the group represents a structure in which six or less aryl or heteroaryl groups which may have one or more substituents are conjugatedly linked, or the same group as a substituent at the ninth or tenth position on the anthracene ring, and n represents an integer of 0 or 1.

Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

Abstract: An organic light emitting device is provided. The organic light emitting device includes a first electrode layer, a second electrode layer and a light emitting material layer. The second electrode layer is disposed opposite to the first electrode layer. The light emitting material layer is disposed between the first electrode layer and the second electrode layer, and includes an organic light emitting material and an electron transport material, wherein the electron transport material includes a compound represented by a formula (1) below: in which a group A represents an aromatic ring, a is 1, and a group B represents a nitrogen containing five-membered heterocyclic group and derivatives thereof, and has at least one nitrogen atom connected to a meta-position of the group A.

Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

Abstract: The invention relates to aqueous, aluminum silicate-free, highly concentrated suspension concentrates, containing the active substance metribuzin, one or more surfactants based on nonionic polymers from the ‘acrylic grafted polymers’ group, one or more thickeners based on anionic heteropolysaccharides from the xanthan gum group, one or more wetting agents and optionally other components such as antifoaming agents, antifreeze agents and preservatives and other surfactants differing from the aforesaid components.

Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract: A heterocyclic compound represented by Formula 1 below, and an organic light-emitting diode including the heterocyclic compound, and a flat display device including the organic light-emitting diode. wherein Ar1 to Ar4, X1, X2, Y1, Y2, L1, and m are defined as in the specification.

Abstract: A heterocyclic compound represented by Formula 1 below, an organic light-emitting diode including the same, and a flat panel display device including the organic light-emitting diode: where X is *—Ar1 or wherein Ar1, Ar2, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, b, c, and d are as defined in the specification.

Abstract: The organic light-emitting element of the present invention is an organic light-emitting element constituted by arranging a light-emitting layer between an anode and a cathode, and is characterized in that the light-emitting layer contains a polymer compound comprising a constitutional unit derived from an electron transport polymerizable compound represented by the following formula (1) and a constitutional unit derived from a phosphorescent polymerizable compound; wherein R1 to R14 are each independently a hydrogen atom, a halogen atom, a cyano group, an amino group, an alkyl group of 1 to 12 carbon atoms or the like, R15 is a hydrogen atom or an alkyl group of 1 to 12 carbon atoms, and X1 is a single bond or the like.

Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: The instant invention relates to novel hydroxyphenyl triazine UV-absorbers with an aromatic carbocyclic fused ring system having a long wavelength shifted absorption spectrum with significant absorbance up to 420 nm. Further aspects of the invention are a process for their preparation, a UV stabilized composition containing the new UV-absorbers, a process for the stabilization of organic materials and the use of the new compounds as UV-light stabilizers for organic materials.

Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).

Abstract: The present invention relates to a material for an organic electroluminescent device, including a phenanthrocarbazole-based compound having a specific structure, and an organic electroluminescent device including the same. More specifically, the phenanthrocarbazole-based compound is applied as a material for a phosphorescent and fluorescent organic electroluminescent device, thereby providing an organic light emitting device with improved light emitting efficiency, luminance, thermal stability, driving voltage, lifetime and the like.

Abstract: The invention relates to compounds of the formula (1), to a method for producing compounds of the formula (1), to the use of the compounds in electronic devices and to electronic devices containing compounds according to formula (1), preferably as electron transport materials, as matrix materials, as electron blocking materials or as emitting materials.

Abstract: There is provided a novel organic compound suitably used for a blue light-emitting device and an organic light-emitting device including the novel organic compound. The organic compound is an acephenanthryleno[4,5-k]benzo[e]acephenanthrylene derivative.

Abstract: A carbazole-based compound of Formula 1 and an organic light-emitting diode including the same. The carbazole-based compound represented by Formula 1 has a triarylamine structure, wherein at least one of R1 to R5 is essentially a nitrogen-containing group. Thus, the carbazole-based compound has high glass transition temperature and/or high melting point, and is stable during electron injection, and when interposed between a pair of electrodes (anode and cathode) of an organic light-emitting diode, the carbazole-based compound may have excellent thermal resistance against Joule's heat generated in organic layers between the pair of electrodes, between the organic layers, or between the organic layer and the electrode during an operation of the organic light-emitting diode.

Abstract: The present invention includes methods, articles, compositions and colorant dyes and pigments that include biocidal N-halamine dye composition having two or more heterocyclic ring structures attached to one or more N-halamine groups, wherein one or more halogens associate with the one or more one or more N-halamine groups to affect biocidal activity.

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including an organic layer that includes the following heterocyclic compound: wherein R1 to R13 are each independently a hydrogen atom, a heavy hydrogen atom, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C3-C60 cycloalkyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C5-C60 aryloxy group, a substituted or unsubstituted C5-C60 arylthio group, a substituted or unsubstituted C5-C60 aryl group, an amino group substituted with a C5-C60 aryl group or a C3-C60 heteroaryl group, a substituted or unsubstituted C3-C60 heteroaryl group, a substituted or unsubstituted C6-C60 condensed polycyclic group, a halogen atom, a cyano group, a nitro group, a hydroxy group, or a carboxy group.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R13 are defined as in the specification.

Abstract: A heterocyclic compound, an organic light-emitting diode, and a flat display device, the heterocyclic compound being represented by Formula 1, below:

Abstract: A heterocyclic compound, organic light-emitting device, and a flat panel display device, the heterocyclic compound being represented by Formula 1 or 2 below:

Abstract: The present invention relates to a substituted pyridyl compound represented by the following general formula (1), (2), or (3) and an organic electroluminescent element containing a pair of electrodes and at least one organic layer interposed therebetween, in which the at least one organic layer contains the substituted pyridyl compound represented by the following general formula (1), (2), or (3).

Abstract: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.

Abstract: There are provided an organic having both excellent hole transporting property and satisfactory electron transporting and showing excellent durability against electric oxidation/reduction and a high triplet excitation level, and a charge transporting material and an organic electroluminescent device each using the organic compound.

Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.

Abstract: A condensed-cyclic compound is represented by Formula 1 below. An organic light-emitting device includes the condensed-cyclic compound. A flat panel display apparatus includes the organic light-emitting device. The organic light-emitting device includes an organic layer including the compound of Formula 1 and has low driving voltage, high emission efficiency, and a long lifetime.

Abstract: The present invention relates to a method for one-pot synthesis of ionic liquid with fluoroalkyl group, more particularly to a method for one-pot synthesis of ionic liquid with fluoroalkyl group represented by the following Chemical Formula 1 by adding and reacting a nitrogen-containing compound, a Brønsted acid of the formula YH and a fluoroolefin compound of the formula CFR1?CR2R3 in a single reactor: wherein represents a nitrogen-containing compound; Y? represents an anion of the Brønsted acid; and R1, R2 and R3, which may be same or different, represent hydrogen, fluorine, C1-C10 alkyl or C1-C10 fluoroalkyl having from 1 to 23 fluorine atoms.

Abstract: A compound for an organic optoelectronic device, an organic light emitting diode, and a display device, the compound being represented by the following Chemical Formula 1:

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.